— Exact Sciences Corp. (NASDAQ: EXAS) reported Q4 2019 earnings of $0.54 per share, vs. a loss of $0.35 expected.
— Total revenues were $295.6 million, vs. $283 million expected.
— Screening revenues increased 60% to $229.4 million.
— Cologuard test volume rose 63% to 477,000.
— Average Cologuard recognized revenue per test was $481.
— Average Cologuard cost per test was $123.
— Precision Oncology proforma revenue increased 14% to $119.1 million.
— FY2020 consolidated revenue is expected to be $1.61-1.64 billion.
— FY2020 Screening revenue is expected to be $1.125-1.15 billion.
— FY2020 Precision Oncology revenue is expected to be $485-495 million.
— EXAS shares gained 1.2% immediately following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Walt Disney (DIS): After a tough FY20, the pandemic is likely to take a toll on operations next year too
The Walt Disney Company (NYSE: DIS) had a tough time in fiscal year 2020 with the COVID-19 pandemic bringing its operations to a standstill like never before. The company incurred
Earnings reports to watch for the week of Nov. 30
The recent optimism about economic recovery waned slightly this week after jobless claims increased more-than-expected to about 778,000 amid concerns over a resurgence in coronavirus cases. With the healthcare system
Yunji Inc. (YJ) Q3 2020 Earnings Call Transcript
Yunji Inc. (NASDAQ: YJ) Q3 2020 earnings call dated Nov. 26, 2020 Corporate Participants: Kaye Liu -- Investor Relations Director Shanglue Xiao -- Chairman of the Board of Directors and Chief Executive Officer Chen